[Neurological complications of neurooncological therapy].
Neurological complications of therapeutic procedures for brain tumors are increasingly being recognized. These encompass the classic types of central and peripheral neurotoxicity, such as radiotherapy-induced leukoencephalopathy and platinum-induced neuropathy. However, the advent of novel protocols and targeted therapeutics has expanded the spectrum of neurological complications. A problem of considerable importance is pseudoprogression after radiochemotherapy with temozolomide. Among the new targeted drugs complications of therapy with bevacizumab are the subject of intense discussion. In this review article the neurotoxic potential of intrathecal chemotherapy, kinase inhibitors, immunological strategies and local therapies are summarized. Knowledge about neurological complications of brain tumor therapy procedures is important for risk assessment and patient information.
Herrlinger
U
U
Schwerpunkt Klinische Neuroonkologie, Neurologische Universitätsklinik Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Deutschland. Ulrich.herrlinger@ukb.uni-bonn.de
Steinbach
J P
JP
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity*; D000068258:Bevacizumab; D001921:Brain / Q000187:drug effects* / Q000528:radiation effects*; D001925:Brain Damage, Chronic / Q000139:chemically induced* / Q000175:diagnosis*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects*; D018572:Disease-Free Survival; D006801:Humans; D007278:Injections, Spinal; D056784:Leukoencephalopathies / Q000175:diagnosis; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000633:toxicity; D010525:Peripheral Nerves / Q000187:drug effects / Q000528:radiation effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000633:toxicity; D011832:Radiation Injuries / Q000175:diagnosis*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D047428:Protein Kinase Inhibitors; D000068258:Bevacizumab